Abstract
Interstitial photodynamic therapy (PDT) is an emerging modality that offers the potential for safe, effective, and repeatable treatment of prostate cancer. We present a Phase I trial utilizing motexafin lutetium (MLu)-mediated PDT in patients with locally recurrent prostate cancer who have previously been treated with definitive radiotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
